TLDR Stopping the drug usually helps, but tamoxifen or surgery may be needed if symptoms persist.
The document reviewed the condition of drug-induced gynecomastia, which was a disorder characterized by the abnormal enlargement of male breast tissue due to an imbalance in estrogen and androgen levels. This condition accounted for 10% to 25% of all gynecomastia cases. Common drugs that could induce this condition included ketoconazole, spironolactone, imatinib, bicalutamide, finasteride, and cimetidine. Symptoms included breast tenderness, pain, and lactation, with laboratory tests showing increased levels of estradiol and estriol, and decreased levels of luteinizing hormone, follicle-stimulating hormone, and testosterone. While most cases were reversible upon discontinuation of the drug, persistent cases could be treated with tamoxifen or surgical removal of breast tissue if symptoms lasted over 1 year or if drug treatment was ineffective. The review aimed to provide clinical guidance based on recent research findings.
6 citations
,
December 2020 in “Dermatological reviews” COVID-19 may worsen with androgens; anti-androgen drugs could help.
Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.
18 citations
,
June 2010 in “Current medicinal chemistry” Treating hirsutism in women often requires a mix of medications and cosmetic methods for best results.
4 citations
,
December 2021 in “Archivio italiano di urologia andrologia” Certain drugs, especially antiandrogens and spironolactone, significantly increase the risk of gynecomastia.
November 2020 in “Elsevier eBooks” Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.
9 citations
,
January 1997 in “Gynecological Endocrinology” The document concludes that treating androgen excess needs patience, managing expectations is important, and many drugs used are not officially approved, suggesting cosmetic options for mild cases.